Leo Pharma partners with Vipergen on dermatology drug discovery

The two firms hope to find new treatments for dermatological diseases using Vipergen’s drug discovery platform.
by andreas lønstrup, translated by daniel pedersen

Dermatology firm Leo Pharma has entered a partnership with Danish firm Vipergen, which provides small molecule drug discovery services based on DNA-encoded library (DEL) technologies, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading